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Phosphatidylinositol (4,5)-bisphosphate (PtdIns(4,5)P2) has been known to serve as a substrate for phosphatidylinositol 3-kinase (PI3K) and
phosphoinositide-specific phospholipase C (PI-PLC), which can produce PtdIns(3,4,5)P3 and inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) and
diacylglycerol (DAG), respectively. In this study, we elucidated the role of PI-PLC during the LPS-activated mouse macrophages RAW264.7
treated with PI3K inhibitor wortmannin. First, wortmannin treatment enhanced Ins(1,4,5)P3 production and iNOS expression in LPS-activated
macrophages. Inhibition of PI3K by p85 siRNA also showed an enhancement of iNOS expression. On the other hand, overexpression of PI3K by
ras-p110 expression plasmid significantly decreased iNOS expression in LPS-activated macrophages. In addition, overexpression of wild-type or
dominant-negative Akt expression plasmid did not affect the iNOS expression in LPS-activated macrophages. Second, treatment of PI-PLC
inhibitor U73122 reversed the enhancement of iNOS expression, the increase of phosphorylation level of ERK, JNK and p38, and the increase of
AP-1-dependent gene expression in wortmannin-treated and LPS-activated macrophages. However, NF-κB activity determined by EMSA assay
and reporter plasmid assay did not change during LPS-activated macrophages with or without wortmannin. We propose that the inhibition of PI3K
by wortmannin in mouse macrophages enhances the PI-PLC downstream signals, and subsequently increases the LPS induction of iNOS
expression independently of Akt pathway.
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The macrophage is a very important cell for development of
an effective immune response to flight infection within the body.
The important functions of macrophages are phagocytosis,
antigen presentation to the T-helper cells, secretion of cytokines,
and storage of iron. Bacterial endotoxin (lipopolysaccharide,
LPS) is an outer membrane component of Gram-negative
bacteria. When LPS binds with a toll-like receptor 4 complex of
out membrane in macrophage, it induces the expression of many
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bolites (e.g. prostaglandins and leukotrienes), nitric oxide (NO),
and several cytokines such as IL-1, TNF-α, IL-6, IL-8, and IL-
12 [1,2]. Nitric oxide (NO) is a multifunctional free radical
produced by the enzyme, nitric oxide synthase (NOS), and plays
a major role in regulating vascular tone, neurotransmission,
killing of microorganisms and tumor cells, and other haemo-
static mechanisms [3]. Inducible NOS (iNOS) is one isoform
that is mainly controlled at the transcriptional level in response
to a wide range of proinflammatory cytokines and bacterial cell
wall products, such as LPS [4]. The molecular mechanisms of
LPS-induced macrophage activation involve several signal
transduction pathways, such as protein kinase A, protein kinase
C (PKC), src-related tyrosine kinases, mitogen-activated protein
kinases (MAPKs): ERK, JNK and p38 [5], and G proteins [6],
which play significant roles in the induction of proinflammatory
gene expression.
The phosphoinositide phosphatidylinositol (4,5)-bispho-
sphate (PtdIns(4,5)P2) is an essential regulator of many cellular
processes and is present in the Golgi, plasma membrane, and the
nucleus. In addition, PtdIns(4,5)P2 can, itself, interact with
actin-regulatory proteins such as profiling and gelsolin to
regulate actin polymerization. It is also present in the nuclear
matrix, heterochromatin and the sites of active RNA splicing,
and is implicated in regulatory RNA splicing, the regulation of
chromatin remodeling, and histone-mediated transcriptional
repression [7–9]. In mammalian cells, PtdIns(4,5)P2 is a
substrate for members of the phosphoinositide-specific phos-
pholipase C (PI-PLC), phosphatidylinositol 3-kinase (PI3K),
and PtdIns(4,5)P2 phosphatase [10], the products of which
contribute to many cellular responses, including cell survival
and inflammation [11,12]. Hydrolysis of PtdIns(4,5)P2 is
catalyzed by PI-PLC to produce the second-messenger
molecules inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) and dia-
cylglycerol (DAG), which in turn mobilize intracellular Ca2+
and activate protein kinase C (PKC), respectively. On the other
hand, PtdIns(4,5)P2 can be phosphorylated by PI3K to generate
PtdIns(3,4,5)P3, which helps to activate downstream Akt
[13,14].
Previous studies have shown that inhibition of PI3K
positively enhanced LPS-induced iNOS expression in mouse
peritoneal macrophages [15] and TNF-α expression in
human monocytic cells [16]. The possible mechanisms
were that activation of PI3K downstream Akt resulted in
the negative regulation of NF-κB, AP-1, and Egr-1
transcriptional activity. PI3K negatively regulated the stability
of cyclooxygenase 2 mRNA in LPS-induced human alveolar
macrophages [17]. Pahan et al. demonstrated that induction
of NOS in C6 glial cells was also regulated negatively by
the activation of PI3K [18]. However, several studies also
have found that activation of PI3K promotes inflammatory
signaling pathways. For example, activation of PI3K-Akt
pathway positively regulated p65 NF-κB transactivation
activity in human hepatoma cells [19], and high Akt activity
could increase NF-κB-dependent gene expression through the
activation of IκB kinase and the p38 in mouse NIH3T3
fibroblasts [20]. These contrasting observations may resultfrom cell type-specific influences of PI3K or the cell type-
specific PI3K subtype. However, this is not yet fully
understood. Recently, Yamaguchi et al. showed that PI3K
inhibitor LY294002 exhibited antitumorigenic properties by
induction of Egr-1 phosphorylation and ATF3 expression in
human colorectal cancer cells [21]. Another PI3K inhibitor,
wortmannin, and dominant-negative Akt had no effect on the
induction of ATF3 expression. The results indicated that
induction of ATF3 expression by LY294002 is independent
of the PI3K/Akt pathway.
Both PI-PLC and PI3K are activated in response to LPS
stimulation and have been shown to play roles in the
signaling cascades triggered by LPS [22,23]. In this study, we
examine the influence of the inhibition of PI3K by wort-
mannin in LPS-induced activation of mouse macrophages.
This inhibition occurs via the increased Ins(1,4,5)P3 formation
by PI-PLC and results in the activation of PKC, MAPKs, AP-1,
and finally, iNOS expression. These effects are caused by
the Akt- and NF-κB-independent pathways. Our study
showed that inhibition of PI3K may go through PI-PLC
pathway leading to increase of iNOS expression, indicating
that PI3K and PI-PLC may counteract to regulate the meta-
bolism of PtdIns(4,5)P2 depending on cells types or their
conditions.2. Materials and methods
2.1. Cell culture and treatments
The mouse macrophage cell lines RAW 264.7 (BCRC 60001, Food Industry
Research and Development Institute, HsinChu, Taiwan) were cultured as
previously described [24]. For all assays except the luciferase assay, cells were
plated in 60-mm dishes at 5×106 cells/dish and allowed to grow for 18–24 h.
LPS (Escherichia coli 0127:B8), wortmannin, and KN93 were purchased from
Sigma Chemical Co. (St Louis, MO). D609, U73122, Chelerythrine chloride,
SP600125, SB203580, U0126 and LY294002 were purchased from Tocris
Bioscience (Ellisville, Missouri), and Bapta-AM was purchased from BIOMOL
(Plymouth Meeting, PA).
2.2. Plasmids and transfection assays
The dominant-negative Akt (DN-Akt), ras-p110, and HA-Akt expression
plasmids were generously provided by Professor Jen-Kun Lin (National Taiwan
University) [25]. The mouse iNOS promoter plasmid (pGL2-iNOS) was
generously provided by Professor Charles J. Lowenstein (Johns Hopkins
University) [26].
For Western blot, cells were seeded in 60-mm dishes. The next day, the cells
were transfected with DN-Akt, HA-Akt, ras-p110 expression plasmids,
scramble control siRNA cocktail, or p85 siRNA cocktail (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA). After 36 h of transfection, the cells
were treated with 50 ng/ml of LPS for another 18 h.
For luciferase reporter assay, cells were seeded in 12-well plates at a density
of 2.5×104. The next day, the cells were replaced the serum-free Opti-MEM
(Invitrogen Corporation, Carlsbad, CA) and transfected with the pGL2-iNOS,
pNF-κB-Luc or pAP-1-Luc reporter plasmids (Stratagene, La Jolla, CA) and
phRL-TK (Promega, Madison, WI) as an internal control plasmid using
LipofectAMINE2000™ (Invitrogen, Carlsbad, CA) [27]. After transfection
(9 h), the medium was replaced with complete medium and continually
incubated for another 39 h. Transfected cells were then directly treated with
drugs for various time periods. Each well was washed twice with cold PBS and
harvested in 150 μl of lysis buffer (0.5 M HEPES pH 7.8, 1% Triton N-101,
1 mMCaCl2, and 1 mMMgCl2). One hundred μl of cell lysate was used to assay
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Instrument Company, Meriden, CT). Luminescence was measured on a Plate
Chameleon Multilabel plate reader. (HIDEX OY, Turku, Finland).
2.3. Western blot
Equal amounts of total cellular protein (50 μg) were resolved by SDS-
polyacrylamide gel electrophoresis (PAGE), and transferred onto Immobilon-P
membrane (Millipore, Bedford, MA) as described previously [27]. The
membrane was then incubated with an anti-iNOS antiserum (BD Biosciences,
San Jose, CA), anti-IκB antiserum, anti-phospho-ERK, anti-ERK, anti-
phospho-JNK, anti-JNK antiserum (Santa Cruz Biotechnology), anti-phos-
pho-p38, anti-p38 antiserum (Cell Signaling Technology, Inc., Danvers, MA),
or anti-α tubulin antiserum (Invitrogen Taiwan, Ltd., Taipei, Taiwan). The
membranes were subsequently probed with anti-mouse or anti-rabbit IgG
antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology)
and visualized using enhanced chemiluminescence kits. The band densities
were quantitated by a computer densitometer (IS-1000 Digital Imaging
System).
2.4. RT-PCR
Total RNA was isolated from both of control and tested cultured cells, and
the mRNA level was detected by RT-PCR as described previously [21]. Four
sets of primers were used to amplify the cDNA of iNOS and GAPDH: iNOS,
forward primer 5′-CCCTTCCGAAGTTTCTGGCAGCAGC-3′, reverse primer
5′-GGCTGTCAGAGAGCCTCGTGGCTTTGG-3′; TNFα, forward primer 5′-
CGAAGGAGTTGGAGGTGTTTTCC-3′, reverse primer 5′-TTTATTGACT-
GAGGCACTGGGG-3′; IL-1β, forward primer 5′-GATCTGGACACT-
CAGGGTCTCATC-3′, reverse primer 5′-GCTCTGTCTTCTTGATGG-
GACCTG-3′; GAPDH, forward primer 5′-ACATCAAGAAGGTGGT-
GAAGC-3′, reverse primer 5′-CTTACTCCTTGGAGGCCATGT-3′. For
measurement of mRNA stability, cells were pretreated with or without
100 nM wortmannin and stimulated with 50 ng/ml LPS for 6 h, followed by
treatment with actinomycin D (4 μg/ml). Total RNA was prepared, and iNOS
mRNA was measured as above. Band densities were quantitated with a
computer densitometer (IS-1000 Digital Imaging System).
2.5. Electrophoretic mobility shift assay (EMSA)
Nuclear proteins and the 32P-labeled double-stranded AP-1 and NF-κB
oligonucleotide probe were prepared as described previously [24]. For DNA
binding reaction, 2 μg of nuclear proteins was mixed with 3 μl of the labeled
probe (approximately 5000 cpm) and 2 μg of poly(dI-dC) poly(dI-dC) in a
reaction buffer (10 mM Tris, pH 7.4, 50 mM NaCl, 5% glycerol, and 1 mM
DTT) for 20 min at room temperature. The DNA–protein complex was
separated on 5% non-denaturing acrylamide gels before vacuum drying and
autoradiography. The specificity of NF-κB or AP-1 binding to its consensus
motif has been proved by supershift experiment as described previously [24].
2.6. Measurement of Ins(1,4,5)P3 levels
Cells were suspended in the PBS buffer, added with 0.2 volume of ice-cold
20% trichloroacetic acid, and kept on ice for 20 min. The protein sediment
was removed by centrifugation at 2000×g for 15 min at 4 °C, and the supernatant
was neutralized with ice-cold 10 M KOH to pH 7.5. The KClO4 sediment was
removed by centrifugation at 2000×g for 15 min at 4 °C. The supernatant
was determined the Ins(1,4,5)P3 level using Inositol-1,4,5-Trisphosphate [
3H]
Radioreceptor Assay Kit (Amersham Biosciences, Piscataway, NJ).
2.7. Kinase assay
Equal amounts of total cellular protein (100 μg) were immunoprecipitated
with JNK or p38 antibody (Santa Cruz Biotechnology) and protein A/G-PLUS
agarose (Santa Cruz Biotechnology) for 16 h at 4 °C. The JNK or p38 kinase
reaction was carried out in a final volume of 40 μl containing 1 μg Gst-ATF2substrate, 10 μM cold ATP, 5 μCi [γ-32p] ATP (5000 Ci/mmol, Amersham) and
incubated for 20 min at 25 °C. Each sample was mixed with 10 μl of
5× Laemmli's loading buffer to stop the reaction, heated for 10 min at 100 °C,
and subjected to SDS-PAGE as described previously [24]. Gels were dried and
visualized by autoradiography.
2.8. Statistical analysis
Data are presented as the mean of S.E. for the indicated number of
independently performed experiments. Statistical analysis was done using one-
way Student's t test.3. Results
3.1. Akt pathway was not involved in the increase of iNOS
expression in wortmannin-treated macrophages
Wortmannin has been shown to inhibit PI3K activity and
result in lower downstream Akt phosphorylation levels. To
test the effect of wortmannin on the inhibition of PI3K
activity in RAW 264.7 macrophage, we detected the
phosphorylation level of Akt by Western blot. The cells
were pretreated with wortmannin for 30 min, then stimulated
with 50 ng/ml LPS for various time periods (0.5–4 h). As
shown in Fig. 1A, 100 nM of wortmannin significantly
inhibited the phosphorylation level of Akt in LPS-activated
macrophages. Next, we found that wortmannin enhanced
LPS-induced iNOS protein expression about 4.2-fold in the
presence or absence of serum (Fig. 1B). In wortmannin-
treated cells, the induction of iNOS protein expression
occurred early, at 4 h after LPS treatment, peaked at 14 h,
and was sustained for 36 h. However, iNOS protein
expression occurred late at 9 h and terminated at 36 h in
the cells treated with LPS alone (Fig. 1C). Further work was
done to determine whether wortmannin enhanced iNOS
expression at the transcription level. RT-PCR results showed
that wortmannin indeed enhanced the iNOS mRNA expres-
sion (Fig. 1D upper panel); indicating that enhancement of
iNOS expression by wortmannin was due to the increase of
iNOS gene expression. Using actinomycin D (an RNA
transcription inhibitor), we examined whether wortmannin
could enhance iNOS mRNA stability and then increase the
mRNA level and its translation product. Results indicated
that wortmannin-enhanced iNOS expression did not result
from enhancing iNOS mRNA stability (data not shown). In
addition, wortmannin also enhanced another two proinflam-
matory genes TNFα and IL-1β expression in LPS-activated
macrophage (Fig. 1D, lower panels). To further investigate
the enhancement of iNOS expression by wortmannin,
transient transfection was performed using mouse iNOS
luciferase promoter construct. Both PI3K inhibitor-wortman-
nin and LY294002 significantly enhanced iNOS promoter
activity in a dose-dependent manner (Fig. 1E).
Wortmannin can inhibit PI3K activity, and therefore limit
Akt activity, but whether it is PI3K, or Akt, or both which
regulate iNOS expression is currently controversial. We used
a ras-p110 expression plasmid that constantly expressed
activated-p110 (PI3K catalytic subunit) or a p85 siRNA
Fig. 1. Inhibition of PI3K resulted in increase of iNOS expression in mouse macrophages. (A–C) Cells were pretreated with PI3K inhibitor-wortmannin (Wort, 100 nM)
for 30 min, then LPS (50 ng/ml) for various times indicated (A, C) or 18 h (B). Total cell lysates were analyzed by Western blot. FBS, fetal bovine serum. (D) Cells
were treated with PI3K inhibitor-wortmannin (100 nM) for 30 min and then LPS (50 ng/ml) for 6 h. Total mRNAwas prepared, and the mRNA levels of iNOS, IL-1β,
TNFα, and GAPDH were detected by RT-PCR. The relative fold of iNOS were quantitated and shown in graphical form (lower). ∗p<0.01 versus LPS treatment. (E)
Cells were transfected with a mouse iNOS reporter plasmid and phRL-TK plasmid as an internal control. After transfection, the cells were treated with PI3K inhibitor-
wortmannin or LY294002 (Ly) for 30 min and then LPS (50 ng/ml) for 8 h. Cells were harvested, and the levels of luciferase activities were determined as described in
Materials and methods. Values are expressed as the mean±S.E. of triplicate tests. ∗p< 0.01 versus LPS treatment.
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expression and then downregulated p110 activity to evaluate
the role of PI3K itself in the regulation of iNOS expression.
As shown in Fig. 2A, LPS induced iNOS expression, and
wortmannin further enhanced the expression in mock
expression cells; however, overexpression of ras-p110 sig-
nificantly limited the induction of iNOS in LPS-activated
cells with or without wortmannin. Transient transfection of
iNOS reporter plasmid also showed that constantly-activated
p110 limited iNOS promoter activity (Fig. 2B). On the other
hand, transient transfection of p85 siRNA significantly
enhanced LPS-induced iNOS expression in comparison to
the cells transfected with scramble control siRNA cocktail
(Fig. 2C, lanes 3 and 4). Next, we evaluated the role of Akt
in the LPS-induced iNOS expression that accompanies
overexpression of wild-type Akt or dominant-negative Akt
(DN-Akt). Interestingly, iNOS expression did not change in
the cell's overexpression of either Akt or DN-Akt in LPS-
activated cells (Fig. 2D, lanes 3 and 5). However, activatedp110 limited LPS-induced iNOS expression (Fig. 2D, lane 4).
These results suggest that PI3K, not Akt, was positively
involved in the regulation of iNOS expression in LPS-
activated macrophages.
3.2. PI-PLC pathway contributes to wortmannin-enhanced
iNOS expression in macrophages
It is well known that PtIns(4,5)P2 can either be phosphory-
lated to form PtdIns(3,4,5)P3 by PI3K or hydrolyzed to form
DAG and Ins(1,4,5)P3 by PI-PLC. Ins(1,4,5)P3 can activate
Akt, but Akt was not involved in the wortmannin-enhanced
iNOS expression in the above experiment. In addition, previous
studies have demonstrated that PI-PLC is involved in the
activation of macrophages and other cell types by LPS treatment
[23,28,29]. Our next experiment examined whether inhibition
of PI3K activity by wortmannin could increase PtdIns(4,5)P2 to
be hydrolyzed by PI-PLC. The Ins(1,4,5)P3 level in the cells
treated with various concentrations of wortmannin and/or LPS
Fig. 2. Activation of PI3K but not Akt resulted in inhibition of iNOS expression. (A, C, D) Cells were transfected with (A) ras-p110 expression plasmid, (C) scramble
control siRNA cocktail (Si Ctl.) or p85 siRNA cocktail (p85 Si), or (D) Akt expression plasmid (wt, wild-type; DN, dominant-negative) for 36 h, and then treated with
LPS (50 ng/ml) for 18 h. Total cell lysate was analyzed by Western blot. The relative fold of iNOS were quantitated and shown in graphical form (lower). ∗p<0.01
versus siRNA control (lane 3). ∗∗p<0.01 versus mock cells with LPS treatment (lane 2). (B) Cells were transfected with ras-p110 expression plasmid, a mouse iNOS
reporter plasmid, and phRL-TK plasmid as an internal control. After transfection, cells were treated with LPS (50 ng/ml) for 8 h. Cells were harvested, and the levels of
luciferase activities were determined as described in Materials and methods. Values are expressed as the mean±S.E. of triplicate tests. ∗p<0.01.
Fig. 3. Inhibition of PI3K resulted in enhancement of Ins(1,4,5)P3 production.
Cells were treated with PI3K inhibitor-wortmannin (25–100 nM) for 30 min
and/or LPS (50 ng/ml) for 10 min, and total cell extract determined the Ins
(1,4,5)P3 content as described in Materials and methods. Values are expressed
as the mean±S.E. of triplicate tests. ∗p<0.01. #p<0.05
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formation and wortmannin enhanced the Ins(1,4,5)P3 formation
in the presence of LPS in a dose-dependent manner. The results
suggest that inhibition of PI3K can increase the PtdIns(4,5)P2
hydrolyzed by PI-PLC.
To further confirm the involvement of the PI-PLC pathway
in the wortmannin-enhanced iNOS expression, the PI-PLC
inhibitor U73122, PC-PLC inhibitor D609, calcium chelator
Bapta-AM, and PKC inhibitor chelerythrine chloride were used.
When cells were pretreated with wortmannin, LPS-induced
iNOS expression was enhanced (Fig. 4A and B, lane 3);
however, the enhancement of iNOS expression disappeared in
U73122-treated cells but not in D609-treated cells (Fig. 4A and
B, lane 5). Activation of PI-PLC can increase DAG and Ins
(1,4,5)P3 levels, and these events subsequently activate PKC
and increase cytoplasmic calcium levels, respectively. As
shown in Fig. 4C and D, the wortmannin-enhanced iNOS
expression was decrease in LPS-activated cells with cheler-
ythrine chloride (Fig. 4C, lane 5); however, Bapta-AM did not
affect the iNOS expression in LPS-activated cells with or
without wortmannin (Fig. 4D, lane 5). These results suggest thatPI-PLC and downstream PKC positively contributed to
wortmannin-enhanced iNOS expression in LPS-activated
macrophages.
Fig. 4. PI-PLC and PKC involved in the iNOS expression of cells treated with PI3K inhibitor. Cells were treated with wortmannin (100 nM) and (A) PI-PLC inhibitor
U73122 (10 μM), (B) PC-PLC inhibitor-D609 (25 μM), (C) PKC inhibitor chelerythrine chloride (1 μM) or (D) calcium chelator Bapta-AM (10 μM) for 30 min and
then LPS (50 ng/ml) for 18 h. Total cell lysates were analyzed by Western blot. In all cases, the relative fold of iNOS were quantitated and shown in graphical form
(lower). #p<0.01 versus LPS treatment alone (lane 2). ∗p<0.01 versus LPS and Wort treatment (lane 3).
874 D.-Z. Liu et al. / Biochimica et Biophysica Acta 1773 (2007) 869–8793.3. AP-1 but not NF-κB mediates wortmannin-enhanced iNOS
expression in macrophages
It is well known that MAPKs, MAPKs downstream AP-1
transcription factor, and NF-κB are the major activated
signaling pathways in LPS-stimulated macrophages. To further
understand the mechanisms by which PI-PLC downstream
pathways positively regulate LPS-induced iNOS expression in
wortmannin-treated cells, we evaluated the effects of wortman-
nin on the phosphorylation level of MAPKs and on the
activation of AP-1 and NF-κB. Exposure of the cells to 50 ng/
ml LPS resulted in a time-dependent phosphorylation of all
three MAPK members, ERK, JNK, and p38 (Fig. 5A). In
addition, wortmannin significantly enhanced the LPS-induced
phosphorylation level of ERK, JNK, and p38 at 1 h and
prolonged the phosphorylation level of ERK for 3 h. However,
wortmannin did not enhance LPS-induced IκB degradation,
indicating that the NF-κB pathway was likely not involved in
wortmannin-enhanced iNOS expression (Fig. 5B). To deter-
mine whether wortmannin can enhance the DNA binding
activity of AP-1 or NF-κB, nuclear extracts were characterized
by EMSA assay. As shown in Fig. 5C, LPS induced AP-1
binding activity at 1 and 2 h, and wortmannin significantly
enhanced the binding activity at 2 h (Fig. 5C, upper). LPS also
induced NF-κB binding activity though wortmannin did not
(Fig. 5C, down). The results approximated those of Western blotanalysis, indicating wortmannin did not affect the activation of
NF-κB in LPS-activated macrophages. The effect of wortman-
nin on gene expression mediated by AP-1 but not NF-κB was
further confirmed in macrophages transfected with reporter
plasmids. As shown in Fig. 5D, LPS induced NF-κB- and AP-1-
dependent gene expression. Moreover, wortmannin signifi-
cantly enhanced AP-1-dependent gene expression, but also did
not affect the NF-κB-dependent gene expression in LPS-
activated cells. These results suggest that the inhibition of PI3K
by wortmannin enhanced AP-1 activity but did not affect NF-
κB activity. Because inhibition of PI3K by wortmannin
enhanced PI-PLC pathways, MAPKs phosphorylation, and
AP-1 activity, we evaluated the effect of the PI-PLC inhibitor
U73122 on reverse MAPKs phosphorylation and AP-1
activation in LPS-activated cells with wortmannin. LPS induced
the phosphorylation of ERK, JNK and p38 (Fig. 6A) in a time-
dependent manner. Pretreatment of cells with wortmannin
enhanced the LPS-induced phosphorylation level of ERK, JNK,
and p38. However, pretreatment of cells with U73122 sig-
nificantly reversed the wortmannin-enhanced phosphorylation
level of ERK, JNK, and p38 in LPS-activated cells. Next, we
examined NF-κB- and AP-1-dependent gene expression by
transient transfection with reporter plasmids. As shown in Fig.
6B and C, wortmannin enhanced AP-1-dependent gene
expression, and U73122 significantly abrogated wortmannin-
enhanced AP-1-dependent gene expression in LPS-activated
Fig. 5. Inhibition of PI3K resulted in enhancement of MAPKs phosphorylation but not NF-κB activity. (A–C) Cells were treated with PI3K inhibitor-wortmannin
(100 nM) for 30 min and then LPS (50 ng/ml) for various times indicated. Total cell lysates were analyzed byWestern blot (A and B), or nuclear proteins were extracted
and analyzed by EMSA assay (C) as described in Materials and methods. (D) Cells were transfected with NF-κB or AP-1 reporter plasmid and phRL-TK plasmid as an
internal control. After transfection, cells were treated with PI3K inhibitor-wortmannin for 30 min and then LPS (50 ng/ml) for 4 h or 8 h. Cells were harvested, and the
levels of luciferase activities were determined as described in Materials and methods. Values are expressed as the mean±S.E. of triplicate tests. ∗p< 0.01. #p> 0.05.
875D.-Z. Liu et al. / Biochimica et Biophysica Acta 1773 (2007) 869–879cells. In contrast, wortmannin and/or U73122 did not affect the
NF-κB-dependent gene expression in LPS-activated cells.
These results suggest that the enhancing effect of wortmannin
on LPS-induced phosphorylation of ERK, JNK, and p38 and
AP-1-dependent gene expression might be mediated by
activation of PI-PLC-dependent signal pathways. To further
understand which MAPKs members are involved in the
enhancement of iNOS expression in wortmannin-treated cells,
three MAPKs members' inhibitors were used. Western blot and
kinase activity assay showed U0126 (1 and 5 μM), SP600125
(10 and 20 μM), and SB203580 (7.5 and 15 μM) dose-
dependently inhibited ERK, JNK, and p38 kinase activity
respectively, indicating these concentrations were effective to
inhibit MAPKs members (Fig. 6D lower panels). Next, we
examined these MAPKs inhibitors on the iNOS expression inwortmannin-treated and LPS-activated cells. As shown in Fig.
6D upper panel, wortmannin enhanced iNOS expression (lane
3) in LPS-activated cells, and U0126 and SP600125 signifi-
cantly abrogated wortmannin-enhanced iNOS expression in a
dose-dependent manner. However, SB203580 did not reverse
the enhancement of iNOS expression in wortmannin- and LPS-
treated cells. These results suggest that ERK and JNK involved
in the wortmannin-enhanced iNOS expression in LPS-activated
cells.
4. Discussion
Several studies have demonstrated Akt to be involved in
the NF-κB signaling pathway in cells treated with PI3K
inhibitor. In the present study, we investigated the effect of a
Fig. 6. Inhibition of PI-PLC resulted in blockade of the MAPKs phosphorylation and AP-1 activity in wortmannin-treated cells. (A) Cells were treated with PI3K
inhibitor-wortmannin (100 nM) and/or PI-PLC inhibitor U73122 (10 μM) for 30 min and then LPS (50 ng/ml) for various times indicated. Total cell lysates were
analyzed by Western blot. #p<0.01 versus LPS treatment alone (lane 2). ∗p<0.01 versus LPS and Wort treatment (lane 4). (B and C) Cells were transfected with AP-1
or NF-κB reporter plasmid and phRL-TK plasmid as an internal control. After transfection, cells were treated with PI3K inhibitor wortmannin (100 nM) and/or PI-PLC
inhibitor U73122 (10 μM) for 30 min and then LPS (50 ng/ml) for 8 h. Cells were harvested, and the levels of luciferase activities were determined as described in
Materials and methods. Values are expressed as the mean±S.E. of triplicate tests. ∗p<0.01. (D) Upper panel, cells were treated with PI3K inhibitor-wortmannin
(100 nM) and MEK1/2 kinase inhibitor U0126 (1 or 5 μM), JNK kinase inhibitor SP600125 (10 or 20 μM), or p38 kinase inhibitor SB203580 (7.5 or 15 μM) for
30 min and then LPS (50 ng/ml) for 18 h. Total cell lysates were analyzed for iNOS expression by Western blot. Lower panels, cells were treated with MEK1/2 kinase
inhibitor U0126 (1 or 5 μM), JNK kinase inhibitor SP600125 (10 or 20 μM), or p38 kinase inhibitor SB203580 (7.5 or 15 μM) for 30 min and then LPS (50 ng/ml) for
45 min. Phosphor-ERK levels were detected byWestern blot, and JNK and p38 kinase activities were detected by kinase activity assay with Gst-ATF-2 as the substrate,
and 32P-labeled Gst-ATF-2 is shown.
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iNOS expression in mouse macrophages. Our results showed
that the inhibition of PI3K by wortmannin did suppress Akt
phosphorylation, but also increased iNOS expression. How-
ever, the overexpression of wild-type Akt or DN-Akt did not
change the iNOS expression in LPS-activated cells. On the
other hand, inhibition of PI3K by wortmannin could increase
PtdIns(4,5)P2 to be hydrolyzed by PI-PLC, leading tosubsequent enhancement of iNOS expression. The results
suggest that this enhancement by wortmannin took place in
an Akt-independent and PI-PLC-dependent manner in LPS-
activated mouse macrophages. Both wortmannin and
LY294002 inhibit PI3K, but they are structurally distinct
compounds. Several reporters have indicated that LY294002
can affect some targets besides PI3K. For example,
LY294002 decreased calcium signaling by serotonin in
Fig. 7. The possible mechanisms for the increase of iNOS expression by
inhibiting PI3K. First, inhibition of PI3K may lead to accumulation of
PtdIns(4,5)P2, resulting in increased conversion of PtdIns(4,5)P2 into DAG
and Ins(1,4,5)P3 by PI-PLC. Second, DAG may activate PKC, and Ins
(1,4,5)P3 may activate unknown signals but not calcium, which in turn
induces iNOS expression. Ins(1,4,5)P3, inositol 1,4,5-trisphosphate; PI3K,
phosphatidylinositol 3-kinase; PtdIns(4,5)P2, phosphatidylinositol 4,5-bispho-
sphate; PtdIns(3,4)P2, phosphatidylinositol 3,4-bisphosphate; PI-PLC, phos-
phoinositide-specific phospholipase C; DAG, diacylglycerol; PKC, protein
kinase C; PTEN, phosphatase and tensin homologue deleted on chromo-
some ten; SHIP, SH2-containing inositol phosphatase.
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[30]. ATF3 induction by LY294002, but not wortmannin,
occurred partially through Egr-1 transcription factor and
independent of the PI3K pathway in human colorectal cancer
cells [17]. Another report demonstrated that LY294002
bound with estrogen receptor and inhibited the estrogen
response gene expression induced by 17β-estradiol [31].
Monocyte chemoattractant protein-1 expression was also
inhibited by LY294002 but through a PI3K-independent
pathway [32]. These results suggest that, unlike wortmannin,
LY294002 has target molecules besides PI3K, and wortman-
nin is a more specific PI3K inhibitor. Interesting, we found
that wortmannin-enhanced iNOS expression was also inde-
pendent of the PI3K/Akt pathway and dependent on the PI-
PLC pathway. Knockdown of PI3K gene by p85 siRNA
enhanced iNOS expression in LPS-activated macrophages. In
contrast, activation of PI3K by transfection of ras-p110
expression plasmid limited the enhancement of iNOS
expression. Furthermore, we found that wortmannin enhanced
Ins(1,4,5)P3 formation in LPS-activated macrophages, and
inhibition of PI-PLC limited the wortmannin-enhanced iNOS
expression. This suggests that the PI-PLC pathway mediates,
at least in part, wortmannin-enhanced iNOS expression in
mouse macrophages.
Although several reports have demonstrated the involve-
ment of the PI-PLC and PC-PLC in LPS-induced iNOS
expression, which one participates in wortmannin-enhanced
iNOS expression is still unknown. In the present study, both
PI-PLC inhibitor U73122 and PC-PLC inhibitor D609
inhibited LPS-induced iNOS expression, but only U73122
markedly limited wortmannin-enhanced iNOS expression
(Fig. 4A and B). Another result showed that wortmannin
increased Ins(1,4,5)P3 production, further suggesting that PI-
PLC was indeed involved in wortmannin-enhanced iNOS
expression. A recent report indicated that PI-PLC activation
might be mediated by protein tyrosine kinase and that PI-PLC
might have led to PtdIns(4,5) hydrolysis in LPS-activated
macrophages [33]. Since it has been demonstrated that
calcium had a opposed role in the regulation of iNOS
expression, that either stimulatory [34,35] or inhibitory
[36,37] effects. Unexpectedly, calcium seems to be unin-
volved in the iNOS expression of mouse RAW264.7
macrophages in this study. When RAW264.7 macrophages
were treated with calcium chelator Bapta-AM, iNOS expres-
sion showed no significant change in LPS-activated cells with
or without wortmannin (Fig. 4D). The results suggest that Ins
(1,4,5)P3 might be mediated by signaling pathways besides
calcium to induce iNOS expression.
To clarify which signal pathways were associated with
wortmannin-enhanced iNOS expression, the phosphorylation
level of MAPKs and IκB degradation, as well as AP-1 and
NF-κB activities, were assessed by Western blot, EMSA
assay, and reporter luciferase assay, respectively. We found
that wortmannin enhanced the phosphorylation level of
MAPKs-ERK, JNK, p38, and AP-1 binding and reporter
activities (Fig. 5). However, IκB degradation and NF-κB
binding and reporter activities were unchanged by wortman-nin treatment. Previous studies have shown that both AP-1
and NF-κB transcription factors play a role in PI3K-Akt
downstream pathways, but NF-κB signaling is controversial
in the regulation of downstream gene expression. Several
reports have demonstrated that PI3K-Akt positively or
negatively regulates NF-κB-dependent gene expression, but
that may be due to different cell types and different inducers.
Other studies have also shown that the antiapoptotic effects of
PI3K-Akt are independent of NF-κB in human hepatocytes
[38]. In this study, we demonstrated that the PI3K/Akt
pathway did not affect the NF-κB activity in wortmannin-
treated cells as determined by IκB degradation, NF-κB
binding assay (EMSA), and reporter plasmid assay. On the
other hand, we showed that the MAPKs pathway and AP-1
transcription factor positively regulated iNOS expression in
wortmannin-treated cells. The phosphorylation level of
MAPKs and AP-1-dependent gene expression fell in
wortmannin-treated cells with U73122. In addition, ERK
inhibitor and JNK inhibitor reversed the enhancement of
iNOS expression in wortmannin- and LPS-treated cells. A
model of LPS induction of iNOS in mouse macrophages was
shown in Fig. 7. The current study suggests that LPS
stimulation of macrophages leads to activation of both the
PI3K and PI-PLC pathways, and that inhibition of PI3K
pathway by wortmannin leads to enhanced PI-PLC down-
stream signals. Enhancement of PI-PLC increases the
formation of DAG and Ins(1,4,5)P3, which then stimulates
PKC, ERK and JNK, AP-1 and other unknown signaling
878 D.-Z. Liu et al. / Biochimica et Biophysica Acta 1773 (2007) 869–879pathways, all of which cooperatively regulate iNOS gene
expression.
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